Le Lézard
Classified in: Health
Subject: FDA

FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADItm (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder


Prescription Drug User Fee Act (PDUFA) action date set for May 23, 2023

PLYMOUTH MEETING, Pa., Dec. 8, 2022 /PRNewswire/ -- Braeburn announces that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injections for subcutaneous (SC) use (CIII) for moderate to severe opioid use disorder was accepted by the U.S. Food and Drug Administration (FDA). The PDUFA action date is set for May 23, 2023. 

About BRIXADI (buprenorphine) Extended-Release Injection for SC Use (CIII) 

BRIXADI is an investigational, extended-release SC injectable therapy under review by FDA for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. If approved, BRIXADI would be used as part of a complete treatment plan that includes counseling and psychosocial support. BRIXADI will be available through a Risk Evaluation and Mitigation Strategy (REMS) program and administered only by healthcare providers in a healthcare setting. 

During the clinical development program, the safety profile of BRIXADI was generally consistent with the known safety profile of oral buprenorphine with the exception of mild-to-moderate injection-site reactions. The most common adverse reactions (occurring in ?5% of patients) associated with BRIXADI administration included injection-site pain, headache, constipation, nausea, injection-site erythema, injection-site pruritus, insomnia and urinary tract infections.

About Braeburn 

Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. At Braeburn, we challenge the status quo and champion transformation of the management of opioid use disorder (OUD) by partnering with the community to help create a world where every person with OUD gets the best possible care and opportunity to reach their full potential. Visit https://braeburnrx.com to learn more. Connect with Braeburn on LinkedIn at https://linkedin.com/company/Braeburn.  

For additional information, please contact:  

Colleen Saltmer: [email protected]

SOURCE Braeburn


These press releases may also interest you

at 12:06
Maid Sailors Cleaning Service has joined forces with Cleaning for a Reason, a non-profit organization offering free house cleaning services to cancer patients across the United States and Canada....

at 12:05
Terragia Biofuel, a technology startup aiming to drive the next generation of biofuels, today announced it has raised a $6 million seed round led by Engine Ventures and Energy Impact Partners (EIP). The company will use the capital to commercialize...

at 12:05
Float, the marketplace moving all the care that doesn't need a hospital to the home, today announced $10 million in Series A funding led by Canvas Ventures, whose General Partner Mike Ghaffary has joined Float's board, with participation from Wave...

at 12:00
V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology's (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. RELIEVE-HF is a randomized, double-blind,...

at 12:00
Critical Path Institute's (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for...

at 11:45
SummaryProduct: Henna cones Issue: Chemical hazard / Product safety What to do: Stop using and selling them immediately and dispose of them in regular household garbage Who this is for: General public / Industry; Retail, Importers IssueHealth Canada...



News published on and distributed by: